US drugmaker Incyte Corporation (Nasdaq: INCY) looked set to open Friday’s trading more than 11% down after taking an after-hours pummelling in the stock market.
The company had announced late on Thursday that the pivotal Phase III GRAVITAS-301 study evaluating itacitinib in combination with corticosteroids for treatment-naïve acute graft-versus-host disease (GVHD), did not meet the primary endpoint.
Compared to placebo plus corticosteroids, itacitinib combination failed to offer a statistically-significant improvement in overall response rate (ORR) at day 28.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze